Selected article for: "baseline value and Covariance Analysis"
Title: Research Communications of the 24th ECVIM-CA Congress
  • Document date: 2015_1_10
    • ID: r59usk02_370
    Snippet: The responder rate was 63% in the amlodipine group and 18% in the placebo group following the dose escalation from day 14 being applied to 54% and 80% of cats receiving amlodipine and placebo respectively. Cats receiving amlodipine were 7.9 (95% CI 2.6 to 24.1) times more likely to be classified as responders when compared to those receiving placebo (logistic regression model, p = 0.0003). From a baseline value of 181.6 AE 12.5 and 179.3 AE 10.8 .....
    Document: The responder rate was 63% in the amlodipine group and 18% in the placebo group following the dose escalation from day 14 being applied to 54% and 80% of cats receiving amlodipine and placebo respectively. Cats receiving amlodipine were 7.9 (95% CI 2.6 to 24.1) times more likely to be classified as responders when compared to those receiving placebo (logistic regression model, p = 0.0003). From a baseline value of 181.6 AE 12.5 and 179.3 AE 10.8 mmHg the mean SBP decreased to 153.6 AE 16.9 mmHg with amlodipine and to 167.7 AE 20.5 mmHg with placebo (repeated measures analysis of covariance model, p < 0.001) by day 28. The responder rate was not influenced by factors other than amlodipine treatment (e.g. baseline blood pressure, concomitant ACE inhibitor therapy, renal disease). There were no differences between the amlodipine and placebo groups in the frequency of adverse events reported during the 28-day blinded phase. Likewise, there were very few changes in the laboratory values over time in either group.

    Search related documents:
    Co phrase search for related documents
    • ACE inhibitor therapy and inhibitor therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • adverse event and ae decrease: 1
    • adverse event and baseline value: 1
    • adverse event and blind phase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32
    • adverse event and blood pressure: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • adverse event and dose escalation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • adverse event and group time: 1, 2, 3
    • adverse event and inhibitor therapy: 1, 2, 3, 4, 5, 6
    • adverse event and logistic regression model: 1, 2, 3, 4, 5, 6
    • adverse event and measure analysis: 1
    • adverse event and placebo group: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29
    • adverse event and regression model: 1, 2, 3, 4, 5, 6, 7
    • adverse event and renal disease: 1, 2, 3
    • adverse event and responder rate: 1, 2, 3, 4, 5, 6, 7